Proportional hazards regression for deaths from CLL-related causes
| . | 10-y death rate (SE) . | Unadjusted hazard ratio (95% CI) . | Log-rank test (P) . | Hazard ratio (95% CI) after adjusting for other 2 independent predictors . | P after adjusting for other 2 independent predictors . |
|---|---|---|---|---|---|
| Independent predictors | |||||
| V gene status | |||||
| Mutated | 6% (3%) | — | — | ||
| Unmutated | 55% (7%) | 14.6 (6.3, 33.9) | < .001 | 6.9 (2.6, 18.3) | < .001 |
| Disease stage | |||||
| A | 15% (3%) | — | — | ||
| B or C | 77% (10%) | 10.2 (5.4, 19.1) | < .001 | 4.6 (2.1, 10.2) | < .001 |
| Chromosome 17 abnormality | |||||
| N | 17% (4%) | — | — | ||
| Y | 100% | 9.1 (4.0, 20.7) | < .001 | 3.3 (1.4, 7.8) | .006 |
| Other factors | |||||
| Karyotype abnormality | |||||
| N | 4% (3%) | — | — | ||
| Y | 35% (5%) | 5.5 (2.1, 14.0) | < .001 | 2.2 (0.8, 6.3) | .13 |
| Chromosome 11 abnormality | |||||
| N | 20% (4%) | — | — | ||
| Y | 45% (12%) | 3.6 (1.8, 7.1) | < .001 | 2.0 (0.8, 5.1) | .14 |
| Karyotype evolution | |||||
| N | 13% (4%) | — | — | ||
| Y | 50% (10%) | 4.1 (2.1, 8.1) | < .001 | 2.0 (0.8, 5.0) | .16 |
| Sex | |||||
| Female | 13% (4%) | — | — | ||
| Male | 36% (6%) | 2.2 (1.2, 4.0) | .01 | 1.7 (0.7, 4.1) | .21 |
| CD38 | |||||
| Less than 30% | 8% (3%) | — | |||
| More than 30% | 39% (8%) | 4.4 (1.9, 9.8) | < .001 | 1.7 (0.6, 4.4) | .29 |
| Morphology | |||||
| Typical | 11% (3%) | — | — | ||
| Atypical | 49% (8%) | 4.2 (2.2, 7.8) | < .001 | 1.1 (0.5, 2.5) | .85 |
| Chromosome 13 abnormality | |||||
| N | 31% (5%) | — | — | ||
| Y | 17% (5%) | 0.6 (0.3, 1.1) | .07 | 0.8 (0.4, 1.8) | .58 |
| Chromosome 12 abnormality | |||||
| N | 18% (4%) | — | — | ||
| Y | 38% (8%) | 2.0 (1.0, 3.7) | .03 | 0.7 (0.3, 1.5) | .34 |
| . | 10-y death rate (SE) . | Unadjusted hazard ratio (95% CI) . | Log-rank test (P) . | Hazard ratio (95% CI) after adjusting for other 2 independent predictors . | P after adjusting for other 2 independent predictors . |
|---|---|---|---|---|---|
| Independent predictors | |||||
| V gene status | |||||
| Mutated | 6% (3%) | — | — | ||
| Unmutated | 55% (7%) | 14.6 (6.3, 33.9) | < .001 | 6.9 (2.6, 18.3) | < .001 |
| Disease stage | |||||
| A | 15% (3%) | — | — | ||
| B or C | 77% (10%) | 10.2 (5.4, 19.1) | < .001 | 4.6 (2.1, 10.2) | < .001 |
| Chromosome 17 abnormality | |||||
| N | 17% (4%) | — | — | ||
| Y | 100% | 9.1 (4.0, 20.7) | < .001 | 3.3 (1.4, 7.8) | .006 |
| Other factors | |||||
| Karyotype abnormality | |||||
| N | 4% (3%) | — | — | ||
| Y | 35% (5%) | 5.5 (2.1, 14.0) | < .001 | 2.2 (0.8, 6.3) | .13 |
| Chromosome 11 abnormality | |||||
| N | 20% (4%) | — | — | ||
| Y | 45% (12%) | 3.6 (1.8, 7.1) | < .001 | 2.0 (0.8, 5.1) | .14 |
| Karyotype evolution | |||||
| N | 13% (4%) | — | — | ||
| Y | 50% (10%) | 4.1 (2.1, 8.1) | < .001 | 2.0 (0.8, 5.0) | .16 |
| Sex | |||||
| Female | 13% (4%) | — | — | ||
| Male | 36% (6%) | 2.2 (1.2, 4.0) | .01 | 1.7 (0.7, 4.1) | .21 |
| CD38 | |||||
| Less than 30% | 8% (3%) | — | |||
| More than 30% | 39% (8%) | 4.4 (1.9, 9.8) | < .001 | 1.7 (0.6, 4.4) | .29 |
| Morphology | |||||
| Typical | 11% (3%) | — | — | ||
| Atypical | 49% (8%) | 4.2 (2.2, 7.8) | < .001 | 1.1 (0.5, 2.5) | .85 |
| Chromosome 13 abnormality | |||||
| N | 31% (5%) | — | — | ||
| Y | 17% (5%) | 0.6 (0.3, 1.1) | .07 | 0.8 (0.4, 1.8) | .58 |
| Chromosome 12 abnormality | |||||
| N | 18% (4%) | — | — | ||
| Y | 38% (8%) | 2.0 (1.0, 3.7) | .03 | 0.7 (0.3, 1.5) | .34 |